CAR-T cell therapy has established itself as an effective treatment option in haematooncology, particularly for B-cell lymphomas. Due to its targeted mechanism of action, it is also increasingly coming into focus for autoimmune diseases - including myasthenia gravis. In this Expert Opinion, Prof. Dr. Dr. Dr. Sven G. Meuth explains why patients with myasthenia gravis could benefit from targeted B-cell depletion using anti-CD19 CAR-T cells and what challenges need to be considered, particularly in a neuroimmunological context.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this Expert Opinion you will know:
- Mechanisms underlying CAR-T cell therapy
- Key differences to monoclonal antibodies
- Challenges in the use of CAR-T cell therapy in neuroimmunology
- Current study results on the therapeutic potential for myasthenia gravis
